These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

648 related items for PubMed ID: 11566042

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR, Sperling RS, Reicin A, Gertz BJ.
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [Abstract] [Full Text] [Related]

  • 4. [COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?].
    Peretz A.
    Rev Med Brux; 2001 Sep; 22(4):A377-80. PubMed ID: 11680204
    [Abstract] [Full Text] [Related]

  • 5. New NSAIDs and gastroduodenal damage.
    Folco GC.
    Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():28-9. PubMed ID: 9032579
    [Abstract] [Full Text] [Related]

  • 6. Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia.
    Linder JD, Mönkemüller KE, Davis JV, Wilcox CM.
    South Med J; 2000 Sep; 93(9):930-2. PubMed ID: 11005360
    [Abstract] [Full Text] [Related]

  • 7. Are rofecoxib and celecoxib safer NSAIDS?
    Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599
    [Abstract] [Full Text] [Related]

  • 8. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
    Ray WA, MacDonald TM, Solomon DH, Graham DJ, Avorn J.
    Pharmacoepidemiol Drug Saf; 2003 Nov; 12(1):67-70. PubMed ID: 12616850
    [No Abstract] [Full Text] [Related]

  • 9. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wynn RL.
    Gen Dent; 2000 Nov; 48(1):16-20. PubMed ID: 11199547
    [No Abstract] [Full Text] [Related]

  • 10. Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
    Umar A, Boisseau M, Yusup A, Upur H, Bégaud B, Moore N.
    Fundam Clin Pharmacol; 2004 Oct; 18(5):559-63. PubMed ID: 15482377
    [Abstract] [Full Text] [Related]

  • 11. [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].
    Lamarque D.
    Bull Cancer; 2004 May; 91 Spec No():S117-24. PubMed ID: 15239340
    [Abstract] [Full Text] [Related]

  • 12. Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor.
    Muscará MN, McKnight W, Asfaha S, Wallace JL.
    Br J Pharmacol; 2000 Feb; 129(4):681-6. PubMed ID: 10683192
    [Abstract] [Full Text] [Related]

  • 13. [Coxibs: cyclooxygenase-2 inhibitors].
    Turnheim K.
    Wien Klin Wochenschr; 2001 Aug 16; 113(15-16):558-65. PubMed ID: 11571832
    [Abstract] [Full Text] [Related]

  • 14. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
    Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J.
    Circulation; 2004 May 04; 109(17):2068-73. PubMed ID: 15096449
    [Abstract] [Full Text] [Related]

  • 15. [Specific COX-2 inhibitors: prospects of therapy with new analgesic and anti-inflammatory substances].
    Hinz B, Brune K.
    Wien Klin Wochenschr; 1999 Feb 12; 111(3):103-12. PubMed ID: 10093892
    [Abstract] [Full Text] [Related]

  • 16. [Selective cyclooxygenase-2 (COX-2) inhibitors: importance and limitations].
    Pairet M, Netter P.
    Therapie; 1999 Feb 12; 54(4):433-45. PubMed ID: 10667110
    [Abstract] [Full Text] [Related]

  • 17. [Selective cyclooxygenase-2 inhibitors and the digestive tract].
    Chaabouni H, Amouri A, Cheikh I, Kchaou M, Ouerghi H, Ben Mami N, Ben Ammar A.
    Tunis Med; 2002 Aug 12; 80(8):427-33. PubMed ID: 12703120
    [Abstract] [Full Text] [Related]

  • 18. Adverse Drug Events Involving COX-2 Inhibitors.
    Verrico MM, Weber RJ, McKaveney TP, Ansani NT, Towers AL.
    Ann Pharmacother; 2003 Sep 12; 37(9):1203-13. PubMed ID: 12921500
    [Abstract] [Full Text] [Related]

  • 19. [COX-2 specific inhibitors: are NSAIDs and the stomach become reconcilied?].
    Bannwarth B.
    Gastroenterol Clin Biol; 2001 Apr 12; 25(4 Suppl):B79-84. PubMed ID: 11449148
    [No Abstract] [Full Text] [Related]

  • 20. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 12; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.